Essential thrombocythemia: genes and variants
Explore variant evidence for Essential thrombocythemia across 5 analyzed proteins (MPL, IFNAR1, IFNAR2, JAK2, JAK3). Linked ClinVar records include 8 pathogenic or likely pathogenic variants, 135 variants of uncertain significance and 16 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Counts refer to the selected disease label.
Data updated 2026-11-05. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Essential thrombocythemia
MPL: Thrombopoietin receptor
Thrombopoietin signaling through this pathway drives megakaryocyte maturation, platelet production, and hematopoietic stem-cell maintenance. Activating variants can cause myeloproliferative neoplasms or hereditary thrombocytosis, whereas loss-of-function variants cause congenital amegakaryocytic thrombocytopenia.
8 ClinVar pathogenic / likely pathogenic and 151 uncertain variants in MPL have source records linked to Essential thrombocythemia. Association strength is not clinical gene validity.
IFNAR1: Interferon alpha/beta receptor 1
Together with IFNAR2, it detects type I interferons and activates JAK-STAT antiviral and immunoregulatory programs. Loss-of-function can impair antiviral defense, while excessive pathway activation contributes to interferon-driven inflammatory disease.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in IFNAR1 have source records linked to Essential thrombocythemia. Association strength is not clinical gene validity.
IFNAR2: Interferon alpha/beta receptor 2
It provides the high-affinity ligand-binding component of the type I interferon receptor complex and triggers antiviral JAK-STAT signaling with IFNAR1. Biallelic loss-of-function variants can predispose to severe viral infections, including critical COVID-19 in some individuals.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in IFNAR2 have source records linked to Essential thrombocythemia. Association strength is not clinical gene validity.
JAK2: Tyrosine-protein kinase JAK2
It transmits signals from erythropoietin, thrombopoietin, growth hormone, and other cytokine receptors into STAT-dependent transcription. The V617F gain-of-function variant is a major driver of polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in JAK2 have source records linked to Essential thrombocythemia. Association strength is not clinical gene validity.
JAK3: Tyrosine-protein kinase JAK3
It carries signals from cytokine receptors using the common gamma chain and is essential for T-cell and NK-cell development. Biallelic loss-of-function variants cause severe combined immunodeficiency, while activating somatic variants occur in selected leukemias and lymphomas.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in JAK3 have source records linked to Essential thrombocythemia. Association strength is not clinical gene validity.
ClinVar pathogenic and likely pathogenic variants linked to Essential thrombocythemia
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| MPL F104S | 104 | Extracellular | Pathogenic / likely pathogenic (★★) |
| MPL R102C | 102 | Extracellular | Pathogenic / likely pathogenic (★★) |
| MPL P136L | 136 | Extracellular | Pathogenic / likely pathogenic (★★) |
| MPL W435C | 435 | Fibronectin type-III 2 | Pathogenic / likely pathogenic (★★) |
| MPL R257C | 257 | Fibronectin type-III 1 | Pathogenic / likely pathogenic (★★) |
| MPL S505N | 505 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| MPL P635L | 635 | Cytoplasmic | Pathogenic / likely pathogenic (★★) |
| MPL R102H | 102 | Extracellular | Pathogenic / likely pathogenic (★) |
Which prediction tools work for Essential thrombocythemia
Observed separation of ClinVar pathogenic / likely pathogenic from benign / likely benign variants (AUROC × 100). This benchmark is not a clinical recommendation.
- MetaLR: 99 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- CATVariant: 97 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaSVM: 96 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- AlphaMissense: 93 out of 100
- SIFT: 90 out of 100
- PolyPhen-2: 84 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- ESM1b (LLR): 79 out of 100
Same protein, different disease
- Congenital amegakaryocytic thrombocytopenia also has ClinVar records linked to MPL variants; they fall partly in the same places as the Essential thrombocythemia variants (19 pathogenic / likely pathogenic).
- Thrombocythemia also has ClinVar records linked to MPL variants; they fall in the same places as the Essential thrombocythemia variants (7 pathogenic / likely pathogenic).
- Primary myelofibrosis also has ClinVar records linked to MPL variants; they fall in the same places as the Essential thrombocythemia variants (5 pathogenic / likely pathogenic).
Diseases related to Essential thrombocythemia
- Multiple myeloma, also linked to IFNAR1 and IFNAR2
- Crohn disease, also linked to JAK2 and JAK3
- Thrombocythemia, also linked to JAK2 and MPL
- Primary myelofibrosis, also linked to JAK2 and MPL
- Melanoma, also linked to IFNAR1 and IFNAR2
- Multiple sclerosis, also linked to IFNAR1 and IFNAR2
- Severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-negative, NK cell-positive, also linked to JAK3
- Severe combined immunodeficiency, also linked to JAK3
- Acute myeloid leukemia, also linked to JAK2
- T-B+ severe combined immunodeficiency due to JAK3 deficiency, also linked to JAK3
- Congenital amegakaryocytic thrombocytopenia, also linked to MPL
- Inflammatory bowel disease, also linked to JAK2
Frequently asked questions
Which genes have records linked to Essential thrombocythemia?
This view contains 5 analyzed proteins: MPL, IFNAR1, IFNAR2, JAK2, JAK3. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 8 pathogenic or likely pathogenic variants, 135 variants of uncertain significance and 16 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 0 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 219 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center